Arbor Biotechnologies
Latest round
- Series C
Last raised
- Mar 2025
Total raised
- $289M
Investors
- 24
About Arbor Biotechnologies
Founded in 2016, based in Massachusetts, US, Arbor Biotechnologies, Inc. is a biotechnology company developing genetic medicines. The company was co-founded by Feng Zhang, Winston Yan, David Scott, and David Walt. In October 2025, Arbor Biotechnologies, Inc. The company is focused on identifying and developing a new generation of genetic therapies using fully owned genomic editors discovered using its machine learning and AI discovery platform. Arbor identifies, screens, and constructs novel editing enzymes and effectors using the discovery platform, which can subsequently be customized to the underlying cause of disease to provide curative medicine for patients. Revenue is primarily derived from strategic partnerships, licensing agreements for its gene editing technologies, and collaborations with pharmaceutical companies.
Who invested in Arbor Biotechnologies
24 investors across 2 rounds
See all investors in Arbor Biotechnologies
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Arbor Biotechnologies
Who invested in Arbor Biotechnologies?
Arbor Biotechnologies has 24 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Arbor Biotechnologies raised?
Arbor Biotechnologies has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Arbor Biotechnologies last raise money?
Arbor Biotechnologies's most recent round on record is a Series C, in Mar 2025.
What does Arbor Biotechnologies do?
Founded in 2016, based in Massachusetts, US, Arbor Biotechnologies, Inc.
Where is Arbor Biotechnologies headquartered?
Arbor Biotechnologies is headquartered in Cambridge, US.
Which VCs invest in companies like Arbor Biotechnologies?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Arbor Biotechnologies's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Arbor Biotechnologies? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.